`
` APPROVAL LETTER
`
`
`
`Bayer HealthCare Pharmaceuticals Inc.
`
`
`Attention: Robert J. Haydu
`
`
`Director, CMC Regulatory Affairs
`
`
`
`100 Bayer Blvd.
`
`
`P.O. Box 915
`
`Whippany, NJ 07981-0915
`
`
`
`Dear Mr. Haydu:
`
`Please refer to your Supplemental New Drug Application (sNDA) dated and received
`
`
`
`June 22, 2020, and your amendments, submitted under section 505(b) of the Federal
`
`
`
`
`Food, Drug, and Cosmetic Act (FDCA) for Stivarga (regorafenib) Tablets, 40 mg.
`
`
`This “Changes Being Effected in 30 days” supplemental new drug application provides
`
`
`
`for the addition of a new 21 tablets per bottle presentation of Stivarga (regorafenib)
`
`Tablets.
`
`
`APPROVAL & LABELING
`
`We have completed our review of this supplemental application, as amended. It is
`
`
`
`
`
`approved, effective on the date of this letter, for use as recommended in the enclosed
`
`
`agreed-upon labeling.
`
`
`CONTENT OF LABELING
`
`
`As soon as possible, but no later than 14 days from the date of this letter, submit the
`
`
`content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using
`
`
`
`
`
`the FDA automated drug registration and listing system (eLIST), as described at
`
`
`
`
`http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm.
`Content of labeling must be identical to the enclosed labeling (text for the prescribing
`
`
`
`information, and text for the patient package insert) with the addition of any labeling
`
`changes in pending “Changes Being Effected” (CBE) supplements, as well as annual
`
`
`reportable changes not included in the enclosed labeling.
`
`
`Information on submitting SPL files using eLIST may be found in the guidance for
`
`
`
`industry titled SPL Standard for Content of Labeling Technical Qs and As at
`
`
`http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guida
`nces/UCM072392.pdf.
`
`
`The SPL will be accessible via publicly available labeling repositories.
`
`
`
`
`
`
`
` NDA 203085/S-014
`
`
`
` U.S. Food & Drug Administration
` Silver Spring, MD 20993
`
`
`
` www.fda.gov
`
`
`
`
`
`
`
`
`
`
`
` NDA 203085/S-014
`
` Page 2
`
`
`
` Also within 14 days, amend all pending supplemental applications that include labeling
` changes for this NDA, including CBE supplements for which FDA has not yet issued an
`
`
`
`
`
`
`
`
` action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format,
` that includes the changes approved in this supplemental application, as well as annual
`
`
`
`
`
` reportable changes, and annotate each change. To facilitate review of your submission,
`
`
` provide a highlighted or marked-up copy that shows all changes, as well as a clean
`
`
`
` Microsoft Word version. The marked-up copy should provide appropriate annotations,
`
`
` including supplement number(s) and annual report date(s).
`
`
`
`
`CARTON AND CONTAINER LABELS
`
`Submit final printed carton and container labels that are identical to enclosed carton and
`
`container labels, as soon as they are available, but no more than 30 days after they are
`printed. Please submit these labels electronically according to the guidance for industry
`
`
`
`Providing Regulatory Submissions in Electronic Format – Certain Human
`
`
`Pharmaceutical Product Applications and Related Submissions Using the eCTD
`
`
`Specifications. For administrative purposes, designate this submission “Product
`
`
`
`Correspondence – Final Printed Carton and Container Labels for approved NDA
`
`
`
`203085/S-014.” Approval of this submission by FDA is not required before the labeling
`
`
`is used.
`
`
`We remind you that you must comply with reporting requirements for an approved NDA
`
`
`
`
`set forth under 21 CFR 314.80 and 314.81.
`
`
`
`If you have any questions, call Yajun Jason Tu, Regulatory Business Process Manager,
`
`at (240) 402 - 4202.
`
`
`
`
`Sincerely,
`
`
`{See appended electronic signature page}
`
`
`
`Ramesh Raghavachari, Ph.D.
`
`Branch Chief, B1
`
`Division of Post-Marketing Activities I
`
`Office of Lifecycle Drug Products
`
`Office of Pharmaceutical Quality
`
`Center for Drug Evaluation and Research
`
`
`
`
`
`Enclosure(s):
`
`Content of Labeling
`
`Carton and Container Labeling
`
`
`
`
`
` U.S. Food & Drug Administration
` Silver Spring, MD 20993
`
`
`
` www.fda.gov
`
`
`
`
`
`Ramesh
`Raghavachari
`
`Digitally signed by Ramesh Raghavachari
`Date: 12/09/2020 01:12:52PM
`GUID: 502d0913000029f375128b0de8c50020
`
`(
`
`
`
`